Xiong Le, Liao Ling-Min, Ding Jian-Wu, Zhang Zhi-Lin, Liu An-Wen, Huang Long
Department of Oncology, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang, Jiangxi, China.
Department of Ultrasound, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
BMC Cancer. 2017 Feb 14;17(1):131. doi: 10.1186/s12885-017-3093-z.
Due to the uncommon nature of primary spinal epidural lymphomas (PSELs), there has been little research looking at prognostic indicators for the tumor. To our knowledge, this is the largest study to evaluate possible clinical and pathologic prognostic factors in PSEL patients.
We retrospectively reviewed 130 cases of PSEL, including 36 Chinese patients and 94 published case reports from 1985 to 2015. Patient treatment regimens included surgery (S; n = 119), surgery followed by chemotherapy (S + CT; n = 25), surgery followed by radiotherapy (S + RT; n = 26), and surgery followed by chemotherapy and radiotherapy (S + CT + RT; n = 50).
Review of the most recent case follow-up data (time varied) found 51 patients (47%) alive and tumor-free, 10 patients (9%) alive with tumor present, and 47 patients (44%) deceased. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 81.1% and 46.3%, respectively. Favorable prognostic factors found by univariate analysis were female sex, B-cell lymphoma diagnosis, cervical spine location, and combined modality treatment. Furthermore, multivariate analysis revealed that thoracic spine location (HR = 4.629, 95% CI = [1.911, 31.667], P = 0.042 for OS) and the lack of combined modality treatment (HR = 12.697, 95% CI = [2.664, 48.612], P < 0.0001 for DFS) were associated with poor survival in PSEL patients.
PSEL demonstrates specific clinical features and is associated with a relatively good prognosis. Thoracic spine location is a significant poor prognostic factor, and combined modality treatment is associated with improved disease-free survival, but not overall survival.
由于原发性脊柱硬膜外淋巴瘤(PSEL)较为罕见,针对该肿瘤预后指标的研究较少。据我们所知,这是评估PSEL患者可能的临床和病理预后因素的最大规模研究。
我们回顾性分析了130例PSEL病例,包括36例中国患者以及1985年至2015年发表的94例病例报告。患者的治疗方案包括手术(S;n = 119)、手术联合化疗(S + CT;n = 25)、手术联合放疗(S + RT;n = 26)以及手术联合化疗和放疗(S + CT + RT;n = 50)。
回顾最新的病例随访数据(时间各异)发现,51例患者(47%)存活且无肿瘤,10例患者(9%)存活但有肿瘤,47例患者(44%)死亡。3年总生存率(OS)和无病生存率(DFS)分别为81.1%和46.3%。单因素分析发现的有利预后因素包括女性、B细胞淋巴瘤诊断、颈椎部位以及综合治疗。此外,多因素分析显示胸椎部位(OS的HR = 4.629,95%CI = [1.911, 31.667],P = 0.042)和缺乏综合治疗(DFS的HR = 12.697,95%CI = [2.664, 48.612],P < 0.0001)与PSEL患者的不良生存相关。
PSEL具有特定的临床特征,且预后相对较好。胸椎部位是一个显著的不良预后因素,综合治疗与无病生存率的提高相关,但与总生存率无关。